24‐hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: Magnitude and duration of antihypertensive effects

Clinical Cardiology

Volumn 14, Issue 9, 1991, Pages 737-742

  Mccarron, David ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

angiotensin converting enzyme inhibitor; hypertension; ramipril

Indexed keywords

PLACEBO; RAMIPRIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BICYCLO COMPOUNDS; BLOOD PRESSURE; BLOOD PRESSURE MONITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGE; RAMIPRIL;

EID: 0025940813     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.4960140908     Document Type: Article

References (33)

1. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure
2. Converting‐enzyme inhibitors in the treatment of hypertension
3. The renin‐angiotensin system and ramipril, a new converting enzyme inhibitor
4. The clinical role of angiotensin converting enzyme inhibitors in antihypertensive therapy in the 1990s
5. Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects
6. Pharmacokinetics and biotransformation of 2‐[N‐[(S)‐1‐ethoxy‐carbonyl‐3‐phenylpropyl]‐L‐alanyl]‐(1S, 3S, 5S)‐2‐azabicyclo[3.3.0]octane‐3‐carboxylic acid (Hoe 498) in rat, dog and man
7. 2‐[N‐[(S)‐1‐ethoxycarbonyl‐3‐phenylpropyl]‐L‐alanyl]‐(1S, 3S, 5S)‐2‐azabicyclo[3.3.0] octane‐3‐carboxylic acid (Hoe 498): Antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats
8. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects
9. Influence of renal function on the pharmacokinetics of ramipril (HOE 498)
10. Steady‐state kinetics of ramipril in renal failure
11. Clinical pharmacology of ramipril
12. Effects of the new oral angiotensin converting enzyme inhibitor 2‐[N‐(S)‐1‐ethoxycarbonyl‐3‐phenyl‐propyl]‐L‐alanyl]‐(1S, 3S, 5S)‐2‐azabicyclo[3.3.0]octane‐3‐carboxylic acid (Hoe 498) in essential hypertension
13. Short‐ and long‐term effects of ramipril in hypertension
14. Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure
15. Efficacy, tolerance, and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension
16. Cardiovascular and renal effects of the converting enzyme inhibitor ramipril in patients with essential hypertension
17. Effects of the angiotensin converting enzyme inhibitor ramipril on proteinuria, blood pressure and renal function in histologically confirmed glomerulonephritis with nephrotic syndrome
18. Cardiovascular and renal effects of ramipril
19. Metabolic effects of ramipril treatment in hypertensive subjects with non‐insulin‐dependent diabetes mellitus
20. Dose‐response relation of the angiotensin converting enzyme inhibitor ramipril in mild to moderate essential hypertension
21. Comparative double‐blind study of ramipril and captopril in mild to moderate essential hypertension
22. An open multicenter study to assess the long‐term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension
23. Effect of ramipril on 24‐hour variability of blood pressure and heart rate in essential hypertension
24. Efficacy and safety of ramipril (HOE 498) in the treatment of hypertension: Dose‐finding study
25. Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man
26. Age‐related effects of angiotensin converting enzyme inhibitors
27. The safety and tolerability of lisinopril in clinical trials
28. Enalapril: A review of human pharmacology
29. Review of the overall experience of captopril in hypertension